NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and Other Influenza Viruses. Geneva: World Health Organization; 2010 Feb.
WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and Other Influenza Viruses.
Show detailsThe literature review and independent evaluation of the validity of recently recommended oseltamivir doses in children by Greg Kearns and Susan Abdel-Rahman is an unpublished report, but is available upon request from the WHO secretariat (see contact information in Part I).
Summary
This report examines available data on oseltamivir's disposition profile in infants and the pathologic and physiologic characteristics that may form the basis for differences between infant and adult populations. Evidence indicates that the standard peroral doses are well tolerated and premature neonates are capable of effectively metabolising oseltamivir and attaining sufficient blood oseltamivir carboxylate levels for antiviral activity. Paediatric pharmokinetic data indicate substantial variability in the dose-plasma concentration relationship, possibly due to oral bioavailability associated with feeding composition and frequency and the maturation of renal function. Dose recommendations for treatment are 2.5-3.0 mg/kg/day for the first 14 days postnatal, 3.0 mg/kg twice daily 0.5 to 12 months of age, and 3-3.5 mg/kg twice daily from 12-24 months. Recommendations are also given for paediatric patients with renal impairment.
- Independent evaluation of oseltamivir dosing in children - WHO Guidelines for Ph...Independent evaluation of oseltamivir dosing in children - WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and Other Influenza Viruses
Your browsing activity is empty.
Activity recording is turned off.
See more...